HEARTS Trial for Thoracic Cancers

Recruiting now · Phase 2

Conditions studied: Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III, Other Cancers in the Thoracic Region

In brief

The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic region near the heart. The main question it aims to answer is whether MRgART affects the heart differently than LINAC. Participants will: * Receive radiation therapy * Undergo MRIs and bloodwork * Complete quality of life questionnaires

Key facts

Study ID

NCT07132918

Run by

University of Wisconsin, Madison

People needed

60

Starts

2025-10-08

Expected to finish

2029-03-01

Last updated by the study team

2026-03-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years at the time of consent.
• Dosimetric eligibility criteria met using endpoints from QUANTEC (>10% of heart receives > 25 Gy) as determined through rapid auto-planning
• Participants with histologically or cytologically proven AJCC, 8th edition including:
• Stage IIB, IIIA, IIIB, IIIC, or IV non-operable non-small cell lung cancer
• Limited stage small cell lung cancer, once daily treatment (excluding twice per day fractionation schemes). Stage I-III N0-2 disease esophageal/esophagogastric cancer
• Stage II or III thymoma/thymic carcinoma
• Other cancers in the thoracic region that meet the dosimetric and other clinical trial criteria, for example lymphoma sarcoma.
• Participants must have a course of daily fractionated RT planned of at least 15 treatment fractions, typically ranging from 1.8 to 4 Gy/fraction

You may not qualify if…

• Definitive clinical or radiologic evidence of metastatic disease with life expectancy <12 months
• Prior thoracic radiotherapy significantly overlapping the heart region
• Contraindications to MRI
• Severe, active co-morbidity defined as follows: New York Heart Association Functional Classification III/IV are not eligible.

Where it is running

• University of Wisconsin - Madison — Madison, Wisconsin, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.